CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 115 filers reported holding CYTOMX THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 0.06 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $51,000 | -50.0% | 18,904 | -18.9% | 0.00% | – |
Q4 2021 | $102,000 | -9.7% | 23,322 | +4.9% | 0.00% | – |
Q3 2021 | $113,000 | -37.2% | 22,232 | -22.0% | 0.00% | -100.0% |
Q2 2021 | $180,000 | -8.2% | 28,508 | +12.2% | 0.00% | 0.0% |
Q1 2021 | $196,000 | +75.0% | 25,408 | +48.3% | 0.00% | – |
Q4 2020 | $112,000 | +30.2% | 17,138 | +32.0% | 0.00% | – |
Q3 2020 | $86,000 | -23.2% | 12,981 | -3.7% | 0.00% | -100.0% |
Q2 2020 | $112,000 | -15.2% | 13,475 | -15.4% | 0.00% | 0.0% |
Q4 2019 | $132,000 | +3.1% | 15,930 | -8.3% | 0.00% | 0.0% |
Q3 2019 | $128,000 | -36.3% | 17,365 | -3.2% | 0.00% | 0.0% |
Q2 2019 | $201,000 | -7.4% | 17,940 | -11.0% | 0.00% | 0.0% |
Q1 2019 | $217,000 | -27.9% | 20,163 | +1.1% | 0.00% | -50.0% |
Q4 2018 | $301,000 | -31.6% | 19,943 | -16.1% | 0.00% | -33.3% |
Q3 2018 | $440,000 | -10.2% | 23,783 | +10.9% | 0.00% | 0.0% |
Q2 2018 | $490,000 | -19.8% | 21,451 | -0.1% | 0.00% | -25.0% |
Q1 2018 | $611,000 | +15.7% | 21,472 | -14.1% | 0.00% | 0.0% |
Q4 2017 | $528,000 | – | 25,006 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Canaan Partners IX LLC | 4,244,381 | $43,378,000 | 100.00% |
VHCP Management II, LLC | 577,831 | $5,905,000 | 3.56% |
REGENTS OF THE UNIVERSITY OF CALIFORNIA | 71,366 | $729,000 | 2.45% |
Casdin Capital, LLC | 234,179 | $2,392,000 | 2.38% |
BVF INC/IL | 606,138 | $6,192,000 | 1.32% |
Opaleye Management Inc. | 160,000 | $1,634,000 | 1.09% |
Redmile Group, LLC | 733,899 | $7,497,000 | 0.72% |
VHCP Management, LLC | 64,200 | $656,000 | 0.68% |
Montecito Bank & Trust | 146,544 | $1,497,000 | 0.63% |
Cormorant Asset Management, LP | 371,636 | $3,796,000 | 0.54% |